To futility but not beyond as Infinity's Hedgehog becomes road kill
This article was originally published in Scrip
Executive Summary
Infinity Pharmaceuticals said it was halting another Phase II trial of its lead candidate, saridegib (also known as IPI-926), a Hedgehog pathway inhibitor, in patients with locally advanced, inoperable chondrosarcoma, a rare and life-threatening cancer of the cartilage. Independent monitors determined that the experimental drug was performing no better than placebo in the disease. The company is also halting an exploratory study of the drug after a disappointing look at the results for the first 12 evaluable patients with myelofibrosis, an incurable malignancy of the bone marrow.